The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Acute Lymphoblastic Leukemia in Children⁎
⁎A separate evidence-based review and position statement are available for the role of SCT in adult ALL patients.34  by unknown
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3SBMT POSITION STATEMENT
he Role of Cytotoxic Therapy with Hematopoietic
tem Cell Transplantation in the Treatment of Acute
ymphoblastic Leukemia in Children*
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3Among the primary objectives of the American
ociety for Blood and Marrow Transplantation are to:
Deﬁne commonly accepted medical practice
Develop standards of medical care for autologous
and allogeneic transplants
Provide recommendations and guidelines about
the role of transplantation as a therapeutic ap-
proach for reimbursement by third-party payers
o this end, in 1999 the Society began the develop-
ent of evidence-based reviews of the scientiﬁc and
A separate evidence-based review and position statement are
vailable for the role of SCT in adult ALL patients.3,4
Expert panel members and authors of the review are: Theresa
ahn, PhD, Roswell Park Cancer Institute, Buffalo, NY; Donna
all, MD, Texas Transplant Institute, San Antonio, TX; Bruce
amitta, MD, Midwest Children’s Center, Medical College of
isconsin and Children’s Hospital of Wisconsin, Milwaukee,
I; Stella Davies, MD, PhD, Cincinnati Children’s Hospital and
edical Center, Cincinnati, OH; Hildy Dillon, MPH, The
eukemia and Lymphoma Society, White Plains, NY; Paul
aynon, MD, Children’s Hospital of Los Angeles, Los Angeles,
A; Richard A. Larson, MD, University of Chicago, Chicago, IL;
usan Parsons, MD, Dana-Farber Cancer Institute/Harvard
edical School, and Tufts New England Medical Center/Tufts
niversity School of Medicine, Boston, MA; Jerome Seidenfeld,
lue Cross and Blue Shield Association Technology Evaluation
enter, Chicago, IL; Daniel Weisdorf, MD, University of
innesota, Minneapolis, MN; Philip L. McCarthy, Jr., MD,
oswell Park Cancer Institute, Buffalo, NY.
Reference: Hahn T, Wall D, Camitta B, et al. The role of
ytotoxic therapy with hematopoietic stem cell transplantation in
he therapy of acute lymphoblastic leukemia in children: an
vidence-based review. Biol Blood Marrow Transplant. 2005;11:
23-861.
Reference: Hahn T, Wall D, Camitta B, et al. The role of
ytotoxic therapy with hematopoietic stem cell transplantation in
he therapy of acute lymphoblastic leukemia in adults: an
vidence-based review. Biol Blood Marrow Transplant. 2006;12:1-
0.
Reference: ASBMT Position Statement: The role of cytotoxic
herapy with hematopoietic stem cell transplantation in the
reatment of acute lymphoblastic leukemia in adults. Biol Blood
arrow Transplant. 2006;12:368-369.
70edical literature to document when blood and mar-
ow transplantation is indicated in the treatment of
elected diseases.
oals
The goals of the evidence-based reviews are to:
Determine which disease will be the subject of
each review, establish the focus for each review,
and develop a list of questions to be addressed
Assemble and critically evaluate all the evidence
regarding the role of cytotoxic therapy with he-
matopoietic stem cell transplantation related to
the disease and the questions to be addressed in
each review
Make treatment recommendations based on the
available evidence
Identify discrepancies in study design or method-
ology among published studies that may impact
the quality of the evidence
Identify needed areas of additional study
uidelines
The following guidelines are offered for the role
f stem cell transplantation (SCT) as therapy for acute
ymphoblastic leukemia (ALL) in children and are
ased on consensus reached by an expert panel1 fol-
owing an evidence-based review of the literature2:
. In ﬁrst complete remission, matched related allo-
geneic SCT demonstrated beneﬁt in very high-risk
Ph pediatric ALL patients and is recommended
over chemotherapy in this patient population.
. Matched related allogeneic SCT in second or sub-
sequent remission has resulted in long-term sur-
vival that may be equivalent to or better than che-
motherapy alone (especially for patients with a
short ﬁrst complete remission). There is insufﬁ-
cient evidence to support a recommendation for
unrelated allogeneic transplant vs. chemotherapy
in this patient population. However, the precise
role of related or unrelated allogeneic SCT in this
setting requires further studies.
. Some pediatric ALL patients with late relapses
achieve extended leukemia-free survival (LFS) with
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ASBMT Position Statement
Ban autologous purged SCT; however, the evidence
is insufﬁcient to determine that this is better than
chemotherapy alone. For those with an early re-
lapse, the outcomes with autologous purged SCT
are less promising.
. There are insufﬁcient data available on the use of
autologous unpurged SCT in the treatment of pe-
diatric ALL; however, this is not recommended as
a priority area of research.
. Outcomes comparing related vs. unrelated donor al-
logeneic SCT have not been adequately studied, es-
pecially in patients who have had high-resolution
typing, and no recommendation can be made at this
time.
. Outcomes of autologous vs. allogeneic SCT have
not been adequately studied and no recommenda-
tion can be made at this time.
. TBI-containing conditioning regimens are recom-
mended as having better outcomes than non–TBI-
containing regimens. T
B & M T. The following are identiﬁed as the most important
areas of needed research:
High quality randomized controlled trials and
other Level I evidence to answer the questions
addressed in this review
Studies to identify patients who are at very high
risk for relapse (in addition to Ph patients) and
for whom more effective treatment approaches
are needed
Studies comparing unrelated marrow or blood do-
nor vs. unrelated cord blood donor allogeneic SCT
Studies comparing alternative, non-family alloge-
neic donor vs. autologous SCT
Studies that address the issue of adolescent and
young adult patients to determine the appropriate
age cut-off for pediatric vs. adult ALL
—Adopted by the ASBMT Executive Committee
on August 18, 2005
2006 American Society for Blood and Marrow
ransplantation
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